Jonathan Harris, Nutter McClennen & Fish LLP Photo

Jonathan A. Harris

Partner / Boston


Jonathan Harris is a partner in Nutter’s Intellectual Property Department and a member of the firm’s Life Sciences group. He regularly advises emerging and established companies in the life sciences industry on all aspects of mission-critical patent matters. A business-minded MBA with two-plus decades of experience, Jonathan is a trusted adviser to companies seeking to protect, license, and enforce patent assets.

Jonathan negotiates and drafts sophisticated patent licenses and strategic alliances. He has prepared and prosecuted over 200 patent applications and regularly counsels clients concerning due diligence and freedom to operate. He has also served as lead or co-lead trial counsel in numerous district court patent actions and inter partes review proceedings, including multiple matters worth billions of dollars.

Notable Experience and Client Impact

Life Science Agreements

  • Patent licenses, collaborations, and commercial agreements: bioMerieux (clinical trial agreements); CoRISMA(medical device) in collaboration with China Grand; Insud Pharma (commercial agreements); Notable (cancer therapeutic) in worldwide collaboration with OncoHeroes; VeraDermics (derm therapeutics) in multiple collaborations and manufacturing agreements
  • University licenses: Cellinfinity (cancer therapeutic) with Ivy League university; Insud Pharma (diagnostic biomarkers)with Canadian university; LeptoX with Ivy League University; VeraDermics with Ivy League university

Patent Litigation

  • Analyze patent portfolios in preparation for Paragraph IV Notice Letters and litigation
  • Served as first chair trial counsel in numerous Paragraph IV patent actions: Cialis® ($2.3 billion annual sales); Lyrica® ($5.1 billion annual sales); Oxycontin® ($1.8 billion annual sales), Reclast®/Zometa® ($1.5 billion annual sales), and Ritalin®/Focalin® ($450 million annual sales)

IP Due Diligence

  • Assess patentability, conduct FTOs, and determine loss of exclusivity dates for multi-billion dollar commercial products and various Phase I-III assets
  • Focus on small and large molecule therapeutics and medical devices

News & Insights



  • The Best Lawyers in America, 2018-2022
  • IAM Patent 1000, 2021

Education & Admissions


University of Connecticut School of Law, J.D., cum laude
University of Connecticut School of Business, MBA, cum laude
Duke University, B.S., Biology


  • Connecticut
  • Massachusetts
  • U.S. Patent and Trademark Office

What Clients Say

  • “Adept at translating complex technical subjects into English.”
  • “Excellent patent analyst with an encyclopedic knowledge of Federal Circuit case law.”
  • “Great in the courtroom. Articulate and quick on his feet.”


  • The Best Lawyers in America, 2018-2022
  • IAM Patent 1000, 2021
Back to Page